AstraZeneca Announced Forxiga Approved in the EU for Chronic Kidney Disease
AstraZeneca's (NYSE: AZN) Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).